Last reviewed · How we verify

NCT05366361

The Dynamics of Human Atrial Fibrillation

Recruiting now Last updated 17 February 2026
What this trial tests

trial in Atrial Fibrillation in 200 participants. Currently enrolling.

Timeline
18 August 2020
Primary endpoint
30 December 2026
30 December 2027

Quick facts

Lead sponsorStanford University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date18 August 2020
Primary completion30 December 2026
Estimated completion30 December 2027
Sites1 location across United States

Conditions studied

Sponsor

Stanford University

Who can join

Adults 22 to 80, any sex, with Atrial Fibrillation or Arrhythmias, Cardiac. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05366361.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing